Advanced searches left 3/3

Car-t cells leukemia - Europe PMC

Summarized by Plex Scholar
Last Updated: 09 November 2022

* If you want to update the article please login/register

Case Report: Successful engraftment of allogeneic hematopoietic stem cells using CAR-T cell therapy as the conditioning regimen in R/R Ph + B cell acute lymphoblastic leukemia.

Background A consolidative allogeneic stem cells transplanted by chimeric antigen receptor T cells therapy is a new form of hematologic malignancies. There is no information on the success of allogeneic hematopoietic stem cell transplantation after CAR-T therapy without a conditioning regimen. Allogeneic stem cells were extracted from an HLA-matched sibling donor and administered to the patient on day 33 during CAR-T cell therapy to treat hematopoiesis. Conclusion We discuss the clinically engraftment of allogeneic HSCs by using CAR-T cell therapy as a conditioning therapy for R/R B-ALL patients.

Source link: https://europepmc.org/article/MED/36225940


Treatment of aggressive T-cell lymphoma/leukemia with anti-CD4 CAR T cells.

We have modified CD4 CAR to cover an IL-15/IL-15sushi complex as IL-15 has been shown to raise the anti-tumor response. In co-culture assays, these CD4-IL15/IL15sushi CAR T cells and NK92 cells effectively destroyed CD4+ leukemic cell lines. In three patients with different T-cell lymphomas, CD4-IL15/IL15sushi CAR T cells were tested for safety in a Phase I clinical trial. These results show that CD4-IL15/IL15sushi CAR T cells may be a safe and effective treatment for patients with relapsed or refractory T-cell lymphomas, where new treatment options are required.

Source link: https://europepmc.org/article/MED/36172388


Generation and proof-of-concept for allogeneic CD123 CAR-Delta One T (DOT) cells in acute myeloid leukemia.

Background Chimeric antigen receptor -T cells have emerged as a breakthrough therapy for relapse/refractory hematological tumors, with remarkably high remission rates. T cells from healthy donors are less dysfunctional or exhausting than autologous patient-derived T cells; in this context, Delta One T cells, a recently described cellular device based on MHC/HLA-independence-independent V3b3+ u03b4 T cells, represent a promising allogeneic platform. CD123CAR-DOTs were able to regulate DOTs, cytotoxicity against AML cell lines and primary samples both in vitro and in vivo, as well as tumor rechallenge.

Source link: https://europepmc.org/article/MED/36162920

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions